Inhibitec Antibodies, S.L. Cantabrian biotechnology company, a spin-off of the CSIC and University of Cantabria, has developed a monoclonal antibody for a new therapeutic target. Last week, it was in Cambridge, within the Idea Spark Program designed by MIT and SODERCAN.
A significant number of psoriatic patients with the severe disease do not respond to existing therapies. A key molecule involved its pathogenic is BAMBI and its inhibition with our specific mAbs (BI0137) prevents skins and articular lesions in preclinical experimental models of psoriasis.